

# LUPIN LIMITED

## SAFETY DATA SHEET

### Section 1: Identification

#### Section 1, Identification

<b>Material</b>	<b>Escitalopram Tablets USP</b> <b>5 mg, 10 mg and 20 mg</b>
<b>Manufacturer</b>	<b>Lupin Limited</b> Goa - 403722 India
<b>Distributor</b>	Lupin Pharmaceuticals, Inc. 111 South Calvert Street, Harborplace Tower, 21st Floor, Baltimore, Maryland 21202 United States Tel. 001-410-576-2000 Fax. 001-410-576-2221

### Section 2: Hazard(s) Identification

#### Section 2, Hazard(s) identification

<b>Fire and Explosion</b>	Expected to be non-combustible.
<b>Health</b>	<p>The use of MAOIs intended to treat psychiatric disorders with escitalopram tablets or within 14 days of stopping treatment with escitalopram tablets is contraindicated because of an increased risk of serotonin syndrome. The use of escitalopram tablets within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated</p> <p>Starting escitalopram tablets in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome.</p> <p>Concomitant use in patients taking pimozide is contraindicated.</p> <p>Escitalopram is contraindicated in patients with a hypersensitivity to escitalopram or citalopram or any of the inactive ingredients in escitalopram tablets.</p>
<b>Environment</b>	No information is available about the potential of this product to produce adverse environmental effects.

### Section 3: Composition/Information on Ingredients

#### Section 3, Composition/information on ingredients

<b>Ingredients</b>	<b>CAS</b>
Escitalopram Oxalate USP	219861-08-2

## Section 4: First-Aid Measures

### Section 4, First-aid measures

<b>Ingestion</b>	Get medical attention. Do not induce vomiting unless directed by medical personnel. Never give anything by mouth to an unconscious person.
<b>Inhalation</b>	Remove to fresh air, If not breathing, give artificial respiration. Get medical attention.
<b>Skin Contact</b>	Wash off immediately with plenty of water. Continue to rinse for at least 15 minutes. Immediately take off all contaminated clothing. Get medical attention if irritation develops and persists.
<b>Eye Contact</b>	Immediately flush eyes with water for at least 15 minutes. If irritation occurs or persists, get medical attention.

### NOTES TO HEALTH PROFESSIONALS

<b>Medical Treatment</b>	Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information center. Protect the patient's airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient's vital signs, blood gases, serum electrolytes, etc.
--------------------------	---

<b>OVERDOSAGE</b>	<p>In clinical trials of escitalopram, there were reports of escitalopram overdose, including overdoses of up to 600 mg, with no associated fatalities. During the postmarketing evaluation of escitalopram, escitalopram overdoses involving overdoses of over 1000 mg have been reported. As with other SSRIs, a fatal outcome in a patient who has taken an overdose of escitalopram has been rarely reported.</p> <p>Symptoms most often accompanying escitalopram overdose, alone or in combination with other drugs and/or alcohol, included convulsions, coma, dizziness, hypotension, insomnia, nausea, vomiting, sinus tachycardia, somnolence, and ECG changes (including QT prolongation and very rare cases of torsade de pointes). Acute renal failure has been very rarely reported accompanying overdose.</p> <p>Establish and maintain an airway to ensure adequate ventilation and oxygenation. Gastric evacuation by lavage and use of activated charcoal should be considered. Careful observation and cardiac and vital sign monitoring are recommended, along with general symptomatic and supportive care. Due to the large volume of distribution of escitalopram, forced diuresis, dialysis, hemoperfusion, and exchange transfusion are unlikely to be of benefit. There are no specific antidotes for escitalopram. In managing overdosage, consider the possibility of multiple-drug involvement. The physician should consider contacting a poison control center for additional information on the treatment of any overdose.</p>
-------------------	--

## Section 5: Fire-Fighting Measures

### Section 5, Fire-fighting measures

<b>Fire and Explosion Hazards</b>	Assume that this product is capable of sustaining combustion.
<b>Extinguishing Media</b>	Water spray, carbon dioxide, dry chemical powder or appropriate foam.
<b>Special Firefighting Procedures</b>	For single units (packages): No special requirements needed.

**Hazardous Combustion Products**

For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapors might be evolved from fires involving this product and associated packaging, self-contained breathing apparatus and full protective equipment are recommended for firefighters.

Hazardous combustion or decomposition products are expected when the product is exposed to fire.

## Section 6: Accidental Release Measures

**Section 6, Accidental release measures****Personal Precautions**

Wear suitable protective clothing, gloves and eye/face protection.

**Environmental Precautions**

Avoid release to the environment.

**Clean-up Methods**

Collect and place it in a suitable, properly labeled container for recovery or disposal.

## Section 7: Handling and Storage

**Section 7, Handling and storage****Handling**

If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment. Wash hands and any exposed skin.

**Storage**

Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

## Section 8: Exposure Controls/Personal Protection

**Section 8, Exposure controls/personal protection**

Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling.

## Section 9: Physical and Chemical Properties

**Section 9, Physical and chemical properties**

Each film coated round tablet contains escitalopram oxalate equivalent to the labeled amount of escitalopram as follows

5 mg Tablets: White to off-white, round, film coated tablets, debossed with "LU" on one side and "W21" on the other side

Bottles of 30	NDC 68180-137-06
Bottles of 100	NDC 68180-137-01
Bottles of 500	NDC 68180-137-02

10 mg Tablets: White to off-white, round, film coated tablets, debossed with 'L' and 'U' either side of the scoreline on one side and 'W22' on the other side.

Bottles of 100	NDC 68180-135-01
Bottles of 500	NDC 68180-135-02
Bottles of 1000	NDC 68180-135-03

20 mg Tablets: White to off-white, round, film coated tablets, debossed with 'L' and 'U' either side of the scoreline on one side and 'W23' on the other side.

Bottles of 100	NDC 68180-136-01
Bottles of 500	NDC 68180-136-02
Bottles of 1000	NDC 68180-136-03

## Section 10: Stability and Reactivity

### Section 10, Stability and reactivity

The product is stable and non-reactive under normal conditions of use, storage and transport.

## Section 11: Toxicological Information

### Section 11, Toxicological information

#### Carcinogenesis, Mutagenesis, Impairment of Fertility

##### Carcinogenesis

Racemic citalopram was administered in the diet to NMRI/BOM strain mice and COBS WI strain rats for 18 and 24 months, respectively. There was no evidence for carcinogenicity of racemic citalopram in mice receiving up to 240 mg/kg/day. There was an increased incidence of small intestine carcinoma in rats receiving 8 or 24 mg/kg/day racemic citalopram.

A no-effect dose for this finding was not established. The relevance of these findings to humans is unknown.

##### Mutagenesis

Racemic citalopram was mutagenic in the *in vitro* bacterial reverse mutation assay (Ames test) in 2 of 5 bacterial strains (Salmonella TA98 and TA1537) in the absence of metabolic activation. It was clastogenic in the *in vitro* Chinese hamster lung cell assay for chromosomal aberrations in the presence and absence of metabolic activation. Racemic citalopram was not mutagenic in the *in vitro* mammalian forward gene mutation assay (HPRT) in mouse lymphoma cells or in a coupled *in vitro/in vivo* unscheduled DNA synthesis (UDS) assay in rat liver. It was not clastogenic in the *in vitro* chromosomal aberration assay in human lymphocytes or in two *in vivo* mouse micronucleus assays.

##### Impairment of Fertility

When racemic citalopram was administered orally to 16 male and 24 female rats prior to and throughout mating and gestation at doses of 32, 48, and 72 mg/kg/day, mating was decreased at all doses, and fertility was decreased at doses  $\geq$  32 mg/kg/day. Gestation duration was increased at 48 mg/kg/day.

## Section 12: Ecological Information

### Section 12: Ecological Information

No relevant studies identified.

## Section 13: Disposal Considerations

### Section 13: Disposal Considerations

Incinerate in an approved facility. Follow all federal state and local environmental regulations.

## Section 14: Transport Information

### Section 14: Transport Information

#### IATA/ICAO - Not Regulated

IATA Proper shipping Name	:	N/A
IATA UN/ID No	:	N/A
IATA Hazard Class	:	N/A
IATA Packaging Group	:	N/A
IATA Label	:	N/A

#### IMDG - Not Regulated

IMDG Proper shipping Name	:	N/A
IMDG UN/ID No	:	N/A
IMDG Hazard Class	:	N/A
IMDG Flash Point	:	N/A
IMDG Label	:	N/A

#### DOT - Not Regulated

DOT Proper shipping Name	:	N/A
DOT UN/ID No	:	N/A
DOT Hazard Class	:	N/A
DOT Flash Point	:	N/A
DOT Packing Group	:	N/A
DOT Label	:	N/A

## Section 15: Regulatory Information

### Section 15: Regulatory Information

This Section Contains Information relevant to compliance with other Federal and/or state laws.

## Section 16: Other Information

### Section 16, Other information

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

**Lupin** shall not be held liable for any damage resulting from handling or from contact with the above product. Lupin reserves the right to revise this SDS.